Delving into the Latest Updates on SYH2067 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

SYH2067

Target-

Action-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Obesity

Inactive Indication-

Originator Organization

CSPC Baike (Shandong) Bio-Pharmaceutical Co., Ltd.

Active Organization

CSPC Baike (Shandong) Bio-Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价SYH2067胶囊在健康受试者中单次和多次给药的安全性和耐受性。次要目的：评价SYH2067胶囊在健康受试者中单次和多次给药的药代动力学特征和药效动力学特征，初步评价食物对SYH2067胶囊单次给药的药代动力学影响

[Translation]

Primary objective: To evaluate the safety and tolerability of single and multiple administrations of SYH2067 capsules in healthy subjects. Secondary objective: To evaluate the pharmacokinetic and pharmacodynamic characteristics of single and multiple administrations of SYH2067 capsules in healthy subjects, and to preliminarily evaluate the effect of food on the pharmacokinetics of single administration of SYH2067 capsules

Start Date10 Apr 2025

Sponsor / Collaborator

CSPC Baike (Shandong) Bio-Pharmaceutical Co., Ltd.

100 Clinical Results associated with SYH2067

Login to view more data

100 Translational Medicine associated with SYH2067

Login to view more data

100 Patents (Medical) associated with SYH2067

Login to view more data

100 Deals associated with SYH2067

Login to view more data